Vladimir Todorović


Vladimir Todorović
Šifra: 185550
Prezime i ime: Vladimir Todorović
Titula: dr sci med
Zvanje: redovni profesor
Org. jedinica: Medicinski fakultet
Dopunski rad: da
Honorarno: da

Nastava

Jedinica Program Tip Sem. Predmet P x GP V x GV L x GL
MEDMEDICINAOsnovne3OSNOVI KLINIČKE PRAKSE II.16 x 10 x 00 x 0
MEDMEDICINAOsnovne2OSNOVI KLINIČKE PRAKSE I.16 x 10 x 00 x 0
MEDMEDICINAOsnovne11OSNOVI KLINIČKE ONKOLOGIJE0 x 00 x 00 x 0
MEDMEDICINAOsnovne5VJEŠTINE KOMUNIKACIJE U MEDICINI.5 x 10 x 00 x 0
MEDMEDICINAOsnovne11ONKOLOGIJA2 x 12 x 20 x 0

Izabrane publikacije

Godina Kategorija Autori Naslov Izvor
2020SCI, SCIE, SSCI, A&HCI
Feng Du, Wenmiao Wang, Yongsheng Wang, Ming Li, Anjie Zhu, Jiayu Wang, Ruigang Cai, Fei Ma, Ying Fan, Qing Li, Pin Zhang, Vladimir Todorovic, Peng Yuan & Binghe XuCarboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancerBreast Cancer Res Treat
2020SCI, SCIE, SSCI, A&HCI
Belkacemi Y, Grellier N, Ghith S, Debbi K, Coraggio G, Bounedjar A, Samlali R, Tsoutsou PG, Ozsahin M, Chauvet MP, Turkan S, Boussen H, Kuten A, Tesanovic D, Errihani H, Benna F, Bouzid K, Idbaih A, Mokhtari K, Popovic L, Spano JP, Lotz JP, Cherif A, To H, Kovcin V, Arsovski O, Beslija S, Dzodic R, Markovic I, Vasovic S, Stamatovic L, Radosavljevic D, Radulovic S, Vrbanec D, Sahraoui S, Vasev N, Stojkovski I, Risteski M, Freixa SV, Krengli M, Radosevic N, Mustacchi G, Filipovic M, Kerrou K, Taghian AG, Todorovic V, Geara F, Gligorov J. 1. A review of the international early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low- and middle-income countries. Eur J Cancer
2019SCI, SCIE, SSCI, A&HCI
Todorovic V, Aapro M, Pavlidis N, Arsovski O, Belkacemi Y, Babovic N, Bidard FC, Bourhafour M, Beslija S, Boussen H, Cetnikovic B, Ceric T, Cicmil N, Crnogorac N, Cuedari E, De Laurentis M, Dragovich T, Durutovic I, Dzamic Z, Dzodic R, Eri Z, Geara F, Khalil A, Kerrou K, Knezevic Usaj S, Kovcin V, Koroveshi D, Kristo Pema A, Kuten A, Lakicevic J, Lukovac N, Markovic I, Markovic M, Mijalkovic N, Miladinova D, Milasevic N, Mustachi G, Ognjenovic D, Pantelic A, Popovic L, Radosavljevic D, Radosevic N, Radulovic S, Ristevski M, Rosic I, Secen N, Sorat M, Stamatovic L, Stefanovski P, Stojkovski I, Tesanovic D, Tomasevic Z, Tomasevic Z, Tsoutsou P, Turkan S, Vasev N, Vasovic S, Vicko F, Vrbanec D, Vukmirovic F, Vrdoljak E, Zaric B, Zambrovski JJ, Cavalli F, Gligorov J.AROME-ESO Oncology Consensus Conference: access to cancer care innovations in countries with limited resources. Association of Radiotherapy and Oncology of the Mediterranean Area (AROME-Paris) and European School of Oncology (ESO - Milan).J BUON
2019SCI, SCIE, SSCI, A&HCI
EDUARD VRDOLJAK, GYORGY BODOKY, JACEK JASSEM, RAZVAN POPESCU, ROBERT PIRKER, TANJA ČUFER, SEMIR BEŠLIJA, ALEXANDRU ENIU, VLADIMIR TODOROVIĆ, KATERINA KOPEcKOVÁ, GALIA KURTEVA, ZORICA TOMAŠEVIĆ, AGIM SALLAKU, SNEZHANA SMICHKOSKA, ŽARKO BAJIĆ, BRANIMIR SIKICExpenditures on Oncology Drugs and Cancer Mortality-to- Incidence Ratio in Central and Eastern EuropeOncologist
2017SCI, SCIE, SSCI, A&HCI
Vladimir Todorovic, Nada Cicmil Saric, Jadranka Lakicevic, Milan SoratEvaluation of safety of bevacizumab as second-line treatment of patients with metastatic colorectal cancerJOURNAL OF BUON
2017SCI, SCIE, SSCI, A&HCI
Gligorov J, Richard S, Todorovic VNew anti-HER2 agents: from second-generation tyrosine kinases inhibitors to bifunctional antibodiesCurr Opin Oncol
2017SCI, SCIE, SSCI, A&HCI
Kandolf Sekulovic L, Peris K, Hauschild A, Stratigos A, Grob JJ, Nathan P, Dummer R, Forsea AM, Hoeller C, Gogas H, Demidov L, Lebbe C, Blank C, Olah J, Bastholt L, Herceg D, Neyns B, Vieira R, Hansson J, Rutkowski P, Krajsova I, Bylaite-Bucinskiene M, Zalaudek I, Maric-Brozic J, Babovic N, Banjin M, Putnik K, Weinlich G, Todorovic V, Kirov K, Ocvirk J, Zhukavets A, Kukushkina M, De La Cruz Merino L, Ymeri A, Risteski M, Garbe CMore than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatmentsEur J Cancer
2016SCI, SCIE, SSCI, A&HCI
Vrdoljak E, Bodoky G, Jassem J, Popescu RA, Mardiak J, Pirker R, Čufer T, Bešlija S, Eniu A, Todorović V, Kubáčková K, Kurteva G, Tomašević Z, Sallaku A, Smichkoska S, Bajić Ž, Šikić BICancer Control in Central and Eastern Europe: Current Situation and Recommendations for ImprovementOncologist
2014SCI, SCIE, SSCI, A&HCI
Todorović, V., Damjanović, S. & Lukovac Janjić, N. Targeted therapy in metastatic hereditary Paragangliomas Mitteilungen Klosterneuburg
2014SCI, SCIE, SSCI, A&HCI
Todorović, V.Prevention and management of stomatitis during treatment with EverolimusWulfenia
2011SCI, SCIE, SSCI, A&HCI
Vrdoljak, E., Wojtukiewicz, MZ., Pienkowski, T., Bodoky, G., Berzinec, P., Finek, J., Todorović, V., Borojević, N., Croitoru, A. & South Eastern European Research Oncology GroupCancer epidemiology in Central and South Eastern European countriesCroatian Medical Journal